Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
Pacific Edge Limited
PFGTFPacific Edge Limited, a cancer diagnostics company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up for patients with haematuria who have a low probability of bladder cancer; Cxbladder Detect, which enables the risk stratification of patients with haematuria; and Cxbladder Monitor, a non-invasive surveillance alternative that reduces the burden of repeated cystoscopy in patients with a low risk of recurrence. In addition, the company is developing products for bladder, gastric, colorectal, endometrial cancers, and melanoma. Pacific Edge Limited was incorporated in 2001 and is headquartered in Dunedin, New Zealand. Address: Centre for Innovation, Dunedin, New Zealand, 9016
Analytics
WallStreetin tavoitehinta
–P/E-suhde
–Osinkotuotto
–Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut PFGTF
Osinkoanalytiikka PFGTF
Osinkojen kasvu 5 vuoden aikana
–Jatkuva kasvu
–Maksusuhde 5 vuoden keskiarvo
–Osinkohistoria PFGTF
Osakkeen arvostus PFGTF
Talousasiat PFGTF
Tuloksia | 2019 | Dynamiikka |